Intralipid treatment for women with reproductive failures.
- Resource Type
- Article
- Authors
- Coulam, Carolyn B.
- Source
- American Journal of Reproductive Immunology. Apr2021, Vol. 85 Issue 4, p1-5. 5p.
- Subject
- *RECURRENT miscarriage
*REPRODUCTIVE history
*BIRTH rate
*PREGNANCY outcomes
*KILLER cells
- Language
- ISSN
- 1046-7408
Does intravenous intralipid treatment for reproductive failure enhance live births? The answer to this question is yes, BUT only in patients that have a diagnosis of recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) loss AND demonstrate elevated NK (natural killer) cell density in their endometrial biopsy. Live birth rates have been reported between 33% and 42% among women displaying elevated NK activity with a diagnosis of RIF and 75% and 91% among women experiencing RPL after intralipid infusion. When the pregnancy outcomes of women with a history of reproductive failure and elevated NK cells treated with intralipid were evaluated, the overall live birth rate per cycle of treatment was 61%. The results of published studies suggest that intralipid can be used successfully as a therapeutic option to modulate abnormal NK activity in women with reproductive problems. [ABSTRACT FROM AUTHOR]